Description: Advanced Proteome Therapeutics Corporation is a biotechnology company. The Company is engaged in the development of anti-cancer therapeutics that exploit the properties of a natural human protein. The Company, through its subsidiary, Advanced Proteome Therapeutics Inc. (APTI), develops and commercializes a new technology platform that is intended for the chemical modification of protein therapeutics. The Foundation Trinity Technology is combining anti-cancer therapies in a single agent for targeted delivery to tumors. It is engaged in targeted therapy, immunotherapy and combination therapy. The Company's technology is applicable to the areas of therapeutics and diagnostics, protein drugs and personalized medicine, and is being applied to cancer therapeutics. It is focusing on enabling technology, designed to link antibodies to drugs or toxins, to produce pure and homogeneous antibody-drug conjugates (ADC).
Home Page: www.advancedproteome.com
APC Technical Analysis
8337 Eastlake Drive
Burnaby,
BC
V5A 4W2
Canada
Phone:
604-690-3797
Officers
| Name | Title |
|---|---|
| Mr. Paul John Courtney Woodward | Pres, CEO, Director & Member of Corp. Advisory Board |
| Mr. Kenneth Clifford Phillippe C.A., B.Com., B.Comm, CPA, CA, CPA | Chief Financial Officer |
| Mr. Martin John Courtney Woodward | Sec. & Independent Director |
Exchange: V
Country: CA
Currency: Canadian Dollar (C$)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 2.75 |
| Price-to-Book MRQ: | 0.8172 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | |
| Fiscal Year End: | July |
| Full Time Employees: | 0 |